Imatinib induces mitochondria-dependent apoptosis of the Bcr-Abl-positive K562 cell line and its differentiation toward the erythroid lineage

FASEB J. 2003 Nov;17(14):2160-2. doi: 10.1096/fj.03-0322.
No abstract available

MeSH terms

  • Antineoplastic Agents / pharmacology*
  • Apoptosis*
  • Benzamides
  • Cell Differentiation / drug effects
  • Cell Lineage
  • Enzyme Inhibitors / pharmacology
  • Erythroid Precursor Cells / physiology
  • Fusion Proteins, bcr-abl / analysis
  • Fusion Proteins, bcr-abl / antagonists & inhibitors*
  • Fusion Proteins, bcr-abl / metabolism
  • Humans
  • Imatinib Mesylate
  • K562 Cells
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / metabolism*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology
  • Mitochondria / drug effects*
  • Models, Biological
  • Oligonucleotide Array Sequence Analysis
  • Phosphorylation
  • Piperazines / pharmacology*
  • Proto-Oncogene Proteins c-abl / metabolism
  • Pyrimidines / pharmacology*
  • Signal Transduction

Substances

  • Antineoplastic Agents
  • Benzamides
  • Enzyme Inhibitors
  • Piperazines
  • Pyrimidines
  • Imatinib Mesylate
  • Fusion Proteins, bcr-abl
  • Proto-Oncogene Proteins c-abl